Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. OSE Immunotherapeutics
  6. News
  7. Summary
    OSE   FR0012127173

OSE IMMUNOTHERAPEUTICS

(OSE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

OSE Immunotherapeutics Releases Positive Data For COVID-19 Vaccine Candidate; Shares Up 7%

11/30/2021 | 05:00am EST


© MT Newswires 2021
All news about OSE IMMUNOTHERAPEUTICS
01/25OSE Immunotherapeutics Gets Allowance Notice For Japanese Patent For Cancer Drug
MT
01/25OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi..
AQ
01/25OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi..
CI
01/17OSE Immunotherapeutics CEO Resigns, Interim Successor Named
MT
01/17OSE Immunotherapeutics Announces the Appointment of Dominique Costantini as Interim CEO..
AQ
01/17OSE Immunotherapeutics SA Announces CEO Change
CI
2021OSE Immunotherapeutics Strengthens Leadership Team with the Appointment of Laurence de ..
GL
2021OSE Immunotherapeutics Strengthens Leadership Team with the Appointment of Laurence de ..
GL
2021OSE Immunotherapeutics Adds Chief Business Officer To Bolster Drug Development
MT
2021OSE Immunotherapeutics Sa Announces Executive Changes
CI
More news
Analyst Recommendations on OSE IMMUNOTHERAPEUTICS
More recommendations
Financials
Sales 2021 16,8 M 18,8 M 18,8 M
Net income 2021 -17,9 M -20,0 M -20,0 M
Net cash 2021 1,99 M 2,22 M 2,22 M
P/E ratio 2021 -8,52x
Yield 2021 -
Capitalization 152 M 169 M 169 M
EV / Sales 2021 8,90x
EV / Sales 2022 4,55x
Nbr of Employees 53
Free-Float 63,4%
Chart OSE IMMUNOTHERAPEUTICS
Duration : Period :
OSE Immunotherapeutics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OSE IMMUNOTHERAPEUTICS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 8,31 €
Average target price 16,52 €
Spread / Average Target 98,8%
EPS Revisions
Managers and Directors
Dominique Costantini Chairman & Chief Executive Officer
Anne-Laure Autret-Cornet Chief Financial & Administrative Officer
Nicolas Poirier Chief Scientific Officer & Director
Silvia Comis Head-Clinical Development
Laurence de Schoulepnikoff Chief Operating & Business Officer
Sector and Competitors
1st jan.Capi. (M$)
OSE IMMUNOTHERAPEUTICS-19.16%175
MODERNA, INC.-38.99%62 828
LONZA GROUP AG-20.54%48 784
IQVIA HOLDINGS INC.-17.54%44 443
SEAGEN INC.-20.08%22 592
ICON PUBLIC LIMITED COMPANY-18.28%20 601